Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis.

Article Details

Citation
Copy to clipboard

Sobel JD, Nyirjesy P

Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis.

Future Microbiol. 2021 Dec;16:1453-1461. doi: 10.2217/fmb-2021-0173. Epub 2021 Nov 16.

PubMed ID
34783586 [ View in PubMed
]
Abstract

Recurrent vulvovaginal candidiasis (RVVC) has significant disease, financial and quality-of-life burdens, affects women from all strata of society worldwide, and lacks an approved therapeutic solution. Fluconazole emerged in 2004 as an antifungal for RVVC; it provides symptom control and has been accepted worldwide as a first-line treatment. Its limitations include the development of resistance and a high rate of vulvovaginal candidiasis recurrence after therapy cessation. There is now an improved treatment option on the horizon: oteseconazole - a novel, oral, selective fungal cytochrome P450 enzyme 51 inhibitor, designed to avoid off-target toxicities. In clinical studies to date, oteseconazole has demonstrated impressive efficacy, a positive tolerability profile and hope for a superior RVVC treatment option.

DrugBank Data that Cites this Article

Drugs